Fig. 2From: UK Kidney Association Clinical Practice Guideline: Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibition in Adults with Kidney Disease 2023 UPDATEEffects of SGLT-2 inhibition on kidney disease progression by primary kidney diagnosis (adapted from [4]). *RR in the diabetic kidney disease or nephropathy subgroup excluding SCORED (which did not formally assess primary kidney disease) is 0.59 (95% CI 0.52–0.68). Figure licensed under Creative Commons CC-BY licenseBack to article page